Statins in neurological disorders: An overview and update

Malfitano, Anna Maria; Marasco, Giuseppe; Proto, Maria; Laezza, C.; Gazzerro, Patrizia; Bifulco, Maurizio

doi:10.1016/j.phrs.2014.06.007

Cited by 72 publications

(49 citation statements)

References 143 publications

(129 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Treatment choices that aim to replenish brain dopamine contents such as dopamine precursors (levodopa), those that mimic dopamine actions in the brain [82] and MAO-B inhibitors like Rasagiline [81] are most important medications for PD. In addition drugs like statins that do not influence dopamine content directly, are also helpful in reducing PD complications, potential anti-inflammatory of statins is thought to be involved in this process [86].…”

Section: Gsk-3␤ In Parkinson's Diseasementioning

confidence: 99%

Glycogen synthase kinase-3 beta (GSK-3β) signaling: Implications for Parkinson's disease

Golpich

Amini

Hemmati

et al. 2015

Pharmacological Research

234

175

View full text Add to dashboard Cite

Section: Gsk-3␤ In Parkinson's Diseasementioning

confidence: 99%

Glycogen synthase kinase-3 beta (GSK-3β) signaling: Implications for Parkinson's disease

Golpich

Amini

Hemmati

et al. 2015

Pharmacological Research

234

175

View full text Add to dashboard Cite

“…Statins have action on immune response system 26 Studies have shown that statins reduce the immune response and tissue infiltration. 7 The first mechanism is expressed by the hindrance of antigen presentation.…”

Section: Anti-inflammatory Reactionsmentioning

confidence: 99%

Current Approach for the Treatment of Parkinson’s Disease by Simvastatin: A Review

Babu¹,

Vadivelan²,

Nair³

et al. 2018

J Pharm Sci Innov.

View full text Add to dashboard Cite

Parkinson disease has become one of the common life-threatening health problem in the world. But the pathogenesis and related mechanisms are still unclear. Current therapy of Parkinson's disease (PD) is not satisfactory, which is the use of combinations of levodopa with other dopaminergic agonist but it is symptomatic in nature and does not slow down the disease course. Many studies have revealed that statins which are used as an antihyperlipidemic drug and have the ability to protect the dopaminergic cells from neurodegeneration. They have anti-inflammatory, suppression of oxidative stress, anticoagulation, angiogenesis actions. So in this review, we are trying to find out the actions of statins on Parkinson disease.

show abstract

“…Accumulating evidence shows that in addition to effectively preventing and treating atherosclerosis, these drugs play a role in the prevention and treatment of nervous system diseases, such as epilepsy, stroke, cerebral ischemia, Parkinson's disease, Alzheimer's disease, multiple sclerosis, brain trauma, and other disorders [30,76].…”

Section: Statinsmentioning

confidence: 99%

Exploring novel AEDs from drugs used for treatment of non-epileptic disorders

Zheng

Wang

2016

Expert Review of Neurotherapeutics

View full text Add to dashboard Cite

Epilepsy is a chronic neurological disease. Although many anti-epileptic drugs (AEDs) have been developed for clinical use, they have no effect on 20-30% of patients and do not generally prevent epileptogenesis. Because of the long development cycle for new AEDs and the high cost, increasing efforts are being made to find anti-epileptic effects among drugs that are already listed for the treatment of other diseases and repurpose them as potential anti-epileptic treatments. Here, we review the progress that has been made in this field as a result of animal and clinical trials of drugs such as rapamycin, everolimus, losartan, celecoxib, bumetanide and other non-epileptic drugs. These drugs can prevent the epileptogenesis, reduce the epileptic pathological changes, and even be used to treat intractable epilepsy. Their mechanisms of action are completely different from those of existing AEDs, prompting researchers to change their perspectives in the search for new AEDs. ARTICLE HISTORY

show abstract

Statins in neurological disorders: An overview and update

Cited by 72 publications

References 143 publications

Glycogen synthase kinase-3 beta (GSK-3β) signaling: Implications for Parkinson's disease

Glycogen synthase kinase-3 beta (GSK-3β) signaling: Implications for Parkinson's disease

Current Approach for the Treatment of Parkinson’s Disease by Simvastatin: A Review

Exploring novel AEDs from drugs used for treatment of non-epileptic disorders

Contact Info

Product

Resources

About